Article
Comprehensive analysis of tumor mutation burden and immune microenvironment in prostate cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 Oct 2022
Liao Junqun, Ye Yuan, Xu Xuren
Abstract excerpt
PURPOSE: Prostate adenocarcinoma (PRAD) is a high incidence of malignant tumor of the urinary system and the second most common male cancer in the world. Immune checkpoint inhibitor (ICIS) therapy is becoming a new hope for cancer treatment. METHODS: To realize the possibility of PRAD patients benefiting from ICIS treatment, we analyzed the mutation spectrum of all PRAD patients, calculated the TMB of each PRAD...
Topics
- Biomarkers, Tumor
- Humans
- Immunotherapy
- Male
- Mutation
- Prognosis
- Prostatic Neoplasms
- Tumor Microenvironment
